JAN 24, 2019 10:34 AM PST

Drug Blocks Toxic-Protein Production in ALS

WRITTEN BY: Nouran Amin

Individuals with ALS, frontotemporal dementia, carry a mutation in the gene C9orf72—resulting in repeated DNA sequences. These repetitions result in the production of toxic proteins that are associated with the development of ALS. Now, a new study aims to target a stress response with a known drug that may result in a decrease of toxic-protein production. "Both cellular stress and over-excitation eventually converge into the integrated stress response,” explains first author and graduate student, Thomas Westergard.

Learn more about ALS:

"Understanding what triggers toxic proteins production helped us hone in on drugs that could block them in laboratory tests," says co-senior author Aaron Haeusler, PhD, an Assistant Professor of Neuroscience within the Vickie & Jack Farber Institute for Neuroscience. Specifically, the researchers showed that the stress responses that trigger toxic protein production are similar to what happens during a seizure event.

The known drug used in the study is called ‘Trazodone’ and is currently approved for the treatment of depression and known to act on stress response. Trazodone was tested on models of the disease and was found to indeed inhibit toxic protein production of toxic protein in a cellular model contained the mutation. "This is a significant step forward in our collaborative approach," said co-author Dr. Piera Pasinelli, PhD, who lead the Jefferson Weinberg ALS Center. "Working together allowed us to speed up the research process getting from the identification of the "pathogenic stress" to testing a potentially useful drug. ALS is a complex and heterogenous disease that needs this collaborative approach, with each lab contributing its own expertise, to fill the gaps and to put together this complex puzzle in a systematic and efficient way.”

credit: healthiculture.com

Researchers are now looking forward to expand their studies for other compounds that might work better than trazodone. Results of the study were published in EMBO Molecular Medicine.

Source: Science Daily

About the Author
Master's (MA/MS/Other)
Nouran is a scientist, educator, and life-long learner with a passion for making science more communicable. When not busy in the lab isolating blood macrophages, she enjoys writing on various STEM topics.
You May Also Like
NOV 30, 2022
Neuroscience
Study Shows a High Rate of Negative Effects of Ayahuasca
Study Shows a High Rate of Negative Effects of Ayahuasca
A new study published in PLOS Global Public Health found a high rate of adverse physical and psychological effects from ...
DEC 12, 2022
Drug Discovery & Development
Accelerated Removal of the Previous Approval
Accelerated Removal of the Previous Approval
The FDA’s accelerated approval process had attracted criticism from researchers, FDA advisory committee members, a ...
DEC 17, 2022
Health & Medicine
A Universal Antidote for Drug Overdoses is in Development
A Universal Antidote for Drug Overdoses is in Development
Drug overdose deaths continue to rise in the United States. About 92,000 people died from drug and prescription opi ...
JAN 04, 2023
Health & Medicine
ACER-001- New Drug to Treat Genetic Disorder
ACER-001- New Drug to Treat Genetic Disorder
Urea cycle disorders (UCDs) are genetic conditions most commonly diagnosed in children that result in the body&rsqu ...
JAN 22, 2023
Neuroscience
Research Study Explores the Mysterious Causes of Pediatric Epilepsy
Research Study Explores the Mysterious Causes of Pediatric Epilepsy
Childhood epilepsy affects roughly 4% of the pediatric population, and there are many different types of epilepsy and se ...
JAN 27, 2023
Cancer
A New Immunotherapy Approach for Advanced Colorectal Cancer
A New Immunotherapy Approach for Advanced Colorectal Cancer
With estimates of over 150,000 new cases and over 50,000 deaths in 2022, colorectal cancer (CRC) remains one of the top ...
Loading Comments...